Table 2—

Cardiovascular drug use attributable to type 2 diabetes from 1 year before (ARbefore) and the first until sixth years after (ARafter) the initiation of oral antidiabetic therapy

Cardiovascular drugARbefore (95% CI)ARafter (95% CI)
Cardiac drugs*37.4 (28.0–45.6)29.9 (22.7–36.4)
Diuretics39.9 (33.3–45.9)30.5 (24.7–35.8)
β-blockers31.2 (23.4–38.2)17.3 (9.8–24.1)
Calcium channel blockers42.9 (32.8–51.4)35.1 (27.0–42.4)
ACE inhibitors44.2 (35.0–52.2)49.1 (43.6–54.0)
Lipid-lowering drugs16.1 (−6.2 to 33.6)50.7 (43.4–57.2)
Antithrombotics29.0 (20.0–37.0)23.4 (16.9–29.5)
Miscellaneous antihypertensive drugs40.0 (6.7–61.4)42.5 (21.3–58.0)
Total cardiovascular drugs26.6 (22.2–30.7)22.1 (18.9–25.2)
  • *

    * Includes mainly heart glycosides, antiarrythmics, and nitrates (Anatomical Therapeutic Chemical code CO1);

  • includes mainly α-blockers (Anatomical Therapeutic Chemical code C02).